Document is current
Any future updates will be listed below
-
Authors
Oing, Christoph https://orcid.org/0000-0001-5578-3418
Hentrich, Marcus
Lorch, Anja
Gläser, Dietrich
Rumpold, Holger
Ochsenreither, Sebastian
Richter, Stephan
Dieing, Annette
Zschäbitz, Stefanie
Pereira, Ronnie Rodrigues
Bokemeyer, Carsten
Seidel, Christoph
-
Funding
Funding for this research was provided by:
European Society for Medical Oncology (Translational Research Fellowship)
- License Information
-
More Information
Article History
Received: 21 August 2019
Accepted: 28 October 2019
First Online: 14 December 2019
Compliance with ethical standards
:
: The authors declare no conflict of interest.
: Protocol, CRF, and patient consent to retrospective data collection on palliative treatment of GCT and analysis of outcomes were approved by the Ethical Board of the Hamburg Chamber of Physicians (Ref No. 5423). Off-label use of cabazitaxel outside of a clinical trial was conducted after obtaining written informed consent in accordance with the Declaration of Helsinki 2013, §37. Patients were informed about the investigational nature of this treatment and the underlying preclinical and clinical rationale as well as about pseudonymised data collection on treatment efficacy. No identifying information of individual patients is included in this article.
